These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12356420)

  • 21. Permeability for intestinal absorption: Caco-2 assay and related issues.
    Press B; Di Grandi D
    Curr Drug Metab; 2008 Nov; 9(9):893-900. PubMed ID: 18991586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based prediction of human intestinal membrane permeability for rapid in silico BCS classification.
    Sun L; Liu X; Xiang R; Wu C; Wang Y; Sun Y; Sun J; He Z
    Biopharm Drug Dispos; 2013 Sep; 34(6):321-35. PubMed ID: 23716273
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds.
    Tubic-Grozdanis M; Bolger MB; Langguth P
    AAPS J; 2008; 10(1):213-26. PubMed ID: 18446522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polar molecular surface properties predict the intestinal absorption of drugs in humans.
    Palm K; Stenberg P; Luthman K; Artursson P
    Pharm Res; 1997 May; 14(5):568-71. PubMed ID: 9165525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In silico predictions of ADME-Tox properties: drug absorption.
    Geerts T; Vander Heyden Y
    Comb Chem High Throughput Screen; 2011 Jun; 14(5):339-61. PubMed ID: 21470183
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Strategies for absorption screening in drug discovery and development.
    Bohets H; Annaert P; Mannens G; Van Beijsterveldt L; Anciaux K; Verboven P; Meuldermans W; Lavrijsen K
    Curr Top Med Chem; 2001 Nov; 1(5):367-83. PubMed ID: 11899103
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting Passive Permeability of Drug-like Molecules from Chemical Structure: Where Are We?
    Broccatelli F; Salphati L; Plise E; Cheong J; Gobbi A; Lee ML; Aliagas I
    Mol Pharm; 2016 Dec; 13(12):4199-4208. PubMed ID: 27806577
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of an integrated in vitro-in silico PBPK (physiologically based pharmacokinetic) model to provide estimates of human bioavailability.
    Cai H; Stoner C; Reddy A; Freiwald S; Smith D; Winters R; Stankovic C; Surendran N
    Int J Pharm; 2006 Feb; 308(1-2):133-9. PubMed ID: 16352407
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Passive oral drug absorption can be predicted more reliably by experimental than computational models--fact or myth.
    Linnankoski J; Ranta VP; Yliperttula M; Urtti A
    Eur J Pharm Sci; 2008 Jul; 34(2-3):129-39. PubMed ID: 18455374
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements.
    Larregieu CA; Benet LZ
    AAPS J; 2013 Apr; 15(2):483-97. PubMed ID: 23344793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
    Lin X; Skolnik S; Chen X; Wang J
    Drug Metab Dispos; 2011 Feb; 39(2):265-74. PubMed ID: 21051535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicting human drug pharmacokinetics from in vitro permeability using an absorption-disposition model.
    Fliszar KA; Hill BT; Foster N
    J Pharm Sci; 2007 Aug; 96(8):2161-70. PubMed ID: 17387695
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome.
    Sun D; Yu LX; Hussain MA; Wall DA; Smith RL; Amidon GL
    Curr Opin Drug Discov Devel; 2004 Jan; 7(1):75-85. PubMed ID: 14982151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays.
    Lee JB; Zgair A; Taha DA; Zang X; Kagan L; Kim TH; Kim MG; Yun HY; Fischer PM; Gershkovich P
    Eur J Pharm Biopharm; 2017 May; 114():38-42. PubMed ID: 28088633
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment.
    Tannergren C; Bergendal A; Lennernäs H; Abrahamsson B
    Mol Pharm; 2009; 6(1):60-73. PubMed ID: 19183105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regional intestinal drug permeation: biopharmaceutics and drug development.
    Lennernäs H
    Eur J Pharm Sci; 2014 Jun; 57():333-41. PubMed ID: 23988845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The composite solubility versus pH profile and its role in intestinal absorption prediction.
    Hendriksen BA; Felix MV; Bolger MB
    AAPS PharmSci; 2003; 5(1):E4. PubMed ID: 12713276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of the MechPeff model to predict passive effective intestinal permeability in the different regions of the rodent small intestine and colon.
    Pade D; Jamei M; Rostami-Hodjegan A; Turner DB
    Biopharm Drug Dispos; 2017 Mar; 38(2):94-114. PubMed ID: 28214380
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
    Tsume Y; Amidon GL
    Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.